(Q41478614)

1 October 2017

1 reference

title

Oxazolidinones: new antibacterial agents (English)

1 reference

1 October 2017

Ford CW

1

1 reference

1 October 2017

Hamel JC

2

1 reference

1 October 2017

Stapert D

3

1 reference

1 October 2017

Moerman JK

4

1 reference

1 October 2017

Hutchinson DK

5

1 reference

1 October 2017

Barbachyn MR

6

1 reference

1 October 2017

Zurenko GE

7

1 reference

1 October 2017

publication date

1 May 1997

1 reference

1 October 2017

published in

Trends in Microbiology

1 reference

1 October 2017

volume

5

1 reference

1 October 2017

issue

5

1 reference

1 October 2017

page(s)

196-200

1 reference

In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Outbreak of hospital infection with a strain of Staphylococcus aureus resistant to gentamicin and methicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

International recognition of methicillin-resistant strains of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Control of an outbreak of methicillin-resistant Staphylococcus aureus (MRSA) by hygienic measures in a general intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

World-wide development of antibiotic resistance in pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Antimicrobial resistance among enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Beta-lactamase-producing enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901032-9

7 January 2021

10.1016/S0966-842X(97)01032-9

Identifiers

DOI

1 reference

1 October 2017

1 reference